SUBSCRIBE
SUBSCRIBE

Phase 3

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Eli Lilly Dropped After Primary Goal of Alzheimer’s Study Was Changed
March 15, 2016
 · 
2 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Drug Development
Embattled Bay Area XOMA Terminates Gevokizumab Trials
March 11, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Regeneron, Sanofi’s RA Drug Beats AbbVie’s Blockbuster Humira in Phase III Study
March 11, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Breast Cancer Pipeline Has More than 1,000 Drugs in Development
March 8, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Celldex Stock Chokes as Brain Cancer Trial Halted
March 7, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Hold Their Breath for BioMarin’s Batten’s Disease and Phenylketonuria Data
March 1, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Amid Fierce Competition from GlaxoSmithKline, AstraZeneca PLC and Teva, Two of Genentech’s Asthma Drug Trials Disappoint
February 29, 2016
 · 
2 min read
Drug Development
Pharma’s Big New Cancer Drug May Be An Old Red Dye
February 26, 2016
 · 
1 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Peregrine Stock Crashes After Company Terminates Phase III Trial for Bavituximab
February 26, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC’s $4 Billion Deal
February 25, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 4, 2026
 · 
4 min read
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Load More